BR0210101A - Antineoplastic Combinations - Google Patents

Antineoplastic Combinations

Info

Publication number
BR0210101A
BR0210101A BR0210101-7A BR0210101A BR0210101A BR 0210101 A BR0210101 A BR 0210101A BR 0210101 A BR0210101 A BR 0210101A BR 0210101 A BR0210101 A BR 0210101A
Authority
BR
Brazil
Prior art keywords
antineoplastic
antineoplastic combinations
combinations
neoplasms
treatment
Prior art date
Application number
BR0210101-7A
Other languages
Portuguese (pt)
Inventor
Gary Dukart
James Joseph Gibbons Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0210101A publication Critical patent/BR0210101A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMBINAçõES ANTINEOPLáSTICAS". A presente invenção refere-se ao uso de uma combinação de um inibidor de mTOR e um agente de alquilação antineoplástico no tratamento de neoplasmas."ANTINEOPLASTIC COMBINATIONS". The present invention relates to the use of a combination of an mTOR inhibitor and an antineoplastic alkylating agent in the treatment of neoplasms.

BR0210101-7A 2001-06-01 2002-05-29 Antineoplastic Combinations BR0210101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29519001P 2001-06-01 2001-06-01
US29523601P 2001-06-01 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (1)

Publication Number Publication Date
BR0210101A true BR0210101A (en) 2004-06-08

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210101-7A BR0210101A (en) 2001-06-01 2002-05-29 Antineoplastic Combinations

Country Status (17)

Country Link
EP (1) EP1392286A2 (en)
JP (1) JP2004532883A (en)
KR (1) KR100875611B1 (en)
CN (1) CN100496485C (en)
AU (2) AU2002259309B2 (en)
BR (1) BR0210101A (en)
CA (1) CA2447732A1 (en)
CO (1) CO5540294A2 (en)
EA (1) EA007530B1 (en)
HU (1) HUP0400006A2 (en)
IL (1) IL158800A0 (en)
MX (1) MXPA03010907A (en)
NO (1) NO20035317L (en)
NZ (1) NZ529877A (en)
PL (1) PL367267A1 (en)
SG (1) SG153647A1 (en)
WO (1) WO2002098416A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104116738A (en) * 2001-02-19 2014-10-29 诺华股份有限公司 Cancer treatment
UA83484C2 (en) * 2003-03-05 2008-07-25 Уайт Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition
AR046194A1 (en) 2003-11-04 2005-11-30 Mayo Foundation TREATMENT METHOD OF MANTO CELL LYMPHOMA
CN113952459A (en) 2005-02-03 2022-01-21 综合医院公司 Methods of treating gefitinib resistant cancers
CA2626326C (en) * 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2933875C (en) * 2005-11-21 2018-06-26 Novartis Ag 40-o-(2-hydroxyethyl)-rapamycin for use as a sole drug substance in the treatment of carcinoid tumors arising from the foregut, midgut, or hindgut
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
KR20140019032A (en) 2006-04-05 2014-02-13 노파르티스 아게 Combinations of therapeutic agents for treating cancer
CA3201293A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
SG191676A1 (en) 2008-06-17 2013-07-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
PT2326329T (en) 2008-08-04 2017-02-14 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
KR20190128004A (en) 2009-04-06 2019-11-13 와이어쓰 엘엘씨 Treatment regimen utilizing neratinib for breast cancer
CN103721189A (en) * 2013-12-27 2014-04-16 刘玉含 Meningeoma nursing medicine and preparation method thereof
CN105168204A (en) * 2015-09-06 2015-12-23 江志鑫 Pharmaceutical composition containing mitomycin and capable of resisting colon cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
ATE135583T1 (en) * 1991-06-18 1996-04-15 American Home Prod USE OF RAPAMYCIN TO TREAT T-CELL LYMPHOMA/LEUKEMIA IN ADULTS
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
CN104116738A (en) * 2001-02-19 2014-10-29 诺华股份有限公司 Cancer treatment

Also Published As

Publication number Publication date
EP1392286A2 (en) 2004-03-03
NO20035317L (en) 2003-12-22
EA200301319A1 (en) 2004-04-29
AU2002259309B2 (en) 2008-05-01
WO2002098416A2 (en) 2002-12-12
EA007530B1 (en) 2006-10-27
CN100496485C (en) 2009-06-10
AU2008202690A1 (en) 2008-07-10
CA2447732A1 (en) 2002-12-12
NZ529877A (en) 2006-08-31
JP2004532883A (en) 2004-10-28
WO2002098416A3 (en) 2003-03-13
HUP0400006A2 (en) 2004-04-28
MXPA03010907A (en) 2004-02-17
CO5540294A2 (en) 2005-07-29
IL158800A0 (en) 2004-05-12
SG153647A1 (en) 2009-07-29
NO20035317D0 (en) 2003-11-28
KR20040025923A (en) 2004-03-26
KR100875611B1 (en) 2008-12-24
CN1646120A (en) 2005-07-27
PL367267A1 (en) 2005-02-21

Similar Documents

Publication Publication Date Title
BR0211769A (en) Antineoplastic Combinations
BR0115323A (en) Use of cci-779 as antineoplastic agent
BR0207961A (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases.
BR0210101A (en) Antineoplastic Combinations
BR0208627A (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
DE69907977D1 (en) Pyrrolobenzodiazepine
BR0101304B1 (en) "polyolefin composition comprising a mixture of UV absorbers and use of a mixture of UV absorbers".
BRPI0208558A2 (en) combination of estrogen-gestagen combination and use
SI1337521T1 (en) Salts of an isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
AR027906A1 (en) USE OF OPHTHALM AGENT
BR0110506A (en) Use of il-18 inhibitors for the treatment and / or prevention of atherosclerosis.
ECSP034866A (en) ANTINEOPLASTIC COMBINATIONS
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AR033012A1 (en) ANTINEOPLASIC COMBINATIONS
EG23929A (en) Isoxazolines derivatives and their use as antidepressants
BR0210632A (en) Parasitic disease treatment
BR0012675A (en) Use of il-18 Inhibitors
BR0313230A (en) Use of carboxamides for tinnitus treatment
PT1274426E (en) USE OF THIOAMIDE-OXAZOLIDINONES IN THE TREATMENT OF OSSEA REABSORCA AND OSTEOPOROSIS
DE60136706D1 (en) YCIN-ACRYLOYL DERIVATIVES AND ANTIMETABOLIC AGENTS
IT1302813B1 (en) DEVICE FOR THE DIRECT REDUCTION OF IRON OXIDES AND RELATED PROCEDURE
BR0002640A (en) Use of simethicone to treat ulcerative colitis
HUP0103040A3 (en) High - level source and it's application
IT1316998B1 (en) COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF TOXIC EFFECTS INDUCED BY THE USE OF IMMUNOSOPPRESSING AGENTS.
BR9908664A (en) The use of sodium nitroprusside and its application

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.